BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) saw a significant decrease in short interest in November. As of November 15th, there was short interest totalling 112,100 shares, a decrease of 20.2% from the October 31st total of 140,400 shares. Based on an average daily trading volume, of 367,700 shares, the short-interest ratio is currently 0.3 days. Approximately 1.0% of the company’s shares are sold short.
BioNexus Gene Lab Stock Performance
BioNexus Gene Lab stock traded up $0.09 during trading hours on Monday, hitting $0.32. 23,064,354 shares of the stock traded hands, compared to its average volume of 681,998. BioNexus Gene Lab has a one year low of $0.23 and a one year high of $3.39. The firm’s 50-day moving average price is $0.36 and its two-hundred day moving average price is $0.43.
Institutional Investors Weigh In On BioNexus Gene Lab
A hedge fund recently raised its stake in BioNexus Gene Lab stock. Virtu Financial LLC lifted its holdings in BioNexus Gene Lab Corp. (NASDAQ:BGLC – Free Report) by 79.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,037 shares of the company’s stock after buying an additional 20,888 shares during the quarter. Virtu Financial LLC owned approximately 0.27% of BioNexus Gene Lab worth $33,000 as of its most recent SEC filing. Institutional investors own 18.85% of the company’s stock.
BioNexus Gene Lab Company Profile
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
Featured Articles
- Five stocks we like better than BioNexus Gene Lab
- The 3 Best Blue-Chip Stocks to Buy Now
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
- How to Use the MarketBeat Excel Dividend Calculator
- 4 AI-Powered Fintechs Revolutionizing the Future of Finance
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.